FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

13 results

abacavir and lamivudine
(Abacavir and Lamivudine)
Laurus Labs Limited
Usage: Abacavir and lamivudine tablets are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection when used in combination with other antiretroviral agents.
complera
(emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
Gilead Sciences, Inc.
Usage: COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.
delstrigo
(doravirine, lamivudine, and tenofovir disoproxil fumarate)
Merck Sharp & Dohme LLC
Usage: DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.
descovy
(emtricitabine and tenofovir alafenamide)
Gilead Sciences, Inc.
Usage: DESCOVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents. It is also approved for HIV-1 pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (≥35 kg), excluding those at risk from receptive vaginal sex.
dovato
(dolutegravir sodium and lamivudine)
ViiV Healthcare Company
Usage: DOVATO is indicated for the treatment of HIV-1 infection in adults and adolescents (aged 12 and older, weighing at least 25 kg) either as a complete regimen for those with no prior treatment history or to replace the current regimen in virologically suppressed patients without resistance concerns.
emtriva
(EMTRICITABINE)
Gilead Sciences, Inc.
Usage: EMTRIVA® is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents.
genvoya
(elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
Gilead Sciences, Inc.
Usage: GENVOYA is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥25 kg) with no prior antiretroviral treatment history or to replace an existing regimen in virologically-suppressed patients on a stable regimen for at least six months without treatment failures or resistance.
lamivudine
(lamivudine oral)
Chartwell RX, LLC
Usage: Lamivudine oral solution is indicated in combination with other antiretroviral agents for treating HIV-1 infection. It is not intended for use in hepatitis B virus (HBV) treatment.
odefsey
(emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)
Gilead Sciences, Inc.
Usage: ODEFSEY is indicated for the treatment of HIV-1 infection in patients weighing at least 25 kg, either as initial therapy for those with no prior treatment history and HIV-1 RNA ≤ 100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients.
stribild
(elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
Gilead Sciences, Inc.
Usage: STRIBILD® is indicated for treating HIV-1 in adults and pediatric patients aged 12 and older (weighing at least 35 kg) without prior antiretroviral treatment or to replace a stable regimen in those virologically suppressed for at least 6 months, without resistance to its components.

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class drugs

abacavir and lamivudine

complera

delstrigo

descovy

dovato

emtriva

genvoya

lamivudine

odefsey

stribild